Alterity Therapeutics (ASXATH) has unveiled a new commercial assessment of its lead candidate ATH434, positioning the therapy as a potential first-in-class treatment for Multiple System Atrophy, a rare and debilitating Parkinsonian disorder with no approved therapies. …
Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy
September 29, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep 23
July 10, 2026 - - Podcast -
Disruption is the overdue remedy and how this debate can revitalise the PBS
July 10, 2026 - - Latest News -
Melbourne study links higher tumour radiation dose to longer progression-free survival
July 10, 2026 - - Latest News -
Older Australians are underestimating their personal risk from RSV
July 10, 2026 - - Latest News -
Territory partnership backs digital health push for diabetes, kidney and heart care
July 9, 2026 - - Latest News -
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 - - Latest News -
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News